{"id":402909,"date":"2010-03-08T09:39:20","date_gmt":"2010-03-08T14:39:20","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=67180"},"modified":"2010-03-08T09:39:20","modified_gmt":"2010-03-08T14:39:20","slug":"cell-therapeutics-passes-factory-test","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/402909","title":{"rendered":"Cell Therapeutics Passes Factory Test"},"content":{"rendered":"\n
Biotech<\/a>, FDA<\/a>, cancer<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Cell Therapeutics (NASDAQ: CTIC<\/a>), the Seattle-based company developing pixantrone for non-Hodgkin’s lymphoma, said today that the FDA has certified that a contract manufacturer is ready to make the treatment. The factory, run by NerPharMa in Italy, was inspected and found to be in compliance and acceptable for continued manufacturing,\u00a0 Cell Therapeutics said. The treatment is expected to be examined by an FDA advisory panel on March 22, and the agency has an April 23 deadline to complete its review of whether to clear pixantrone for sale as a treatment for non-Hodgkin’s lymphoma.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, FDA, cancer Luke Timmerman wrote: Cell Therapeutics (NASDAQ: CTIC), the Seattle-based company developing pixantrone for non-Hodgkin’s lymphoma, said today that the FDA has certified that a contract manufacturer is ready to make the treatment. The factory, run by NerPharMa in Italy, was inspected and found to be in compliance and acceptable for continued manufacturing,\u00a0 […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-402909","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/402909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=402909"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/402909\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=402909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=402909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=402909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}